© 2000 by European Society of Cardiology
Copyright © 2000, European Society of Cardiology
Influence of cyclosporine A on contractile function, calcium handling, and energetics in isolated human and rabbit myocardium
Abt. Kardiologie und Pneumologie, Universität Göttingen, Göttingen, Germany
* Corresponding author. Tel.: +49-551-396-380; fax: +49-551-392-953 janssenp{at}med.uni-goettingen.de
Objective:The immunosuppressive drug Cyclosporine A (CsA) is a key substance in pharmacological therapy following solid organ transplantation and has been suggested to prevent cardiac hypertrophy. We investigated the direct effects of CsA on myocardial function, because these are largely unknown. Methods: In multicellular cardiac muscle preparations from end-stage failing and non-failing human hearts as well as from non-failing rabbit hearts we investigated the effects of CsA on contractile performance, sarcoplasmic reticulum (SR) Ca2+-load, cytosolic calcium transients, calcium sensitivity of the myofilaments, and myocardial oxygen consumption. Results: In failing human muscle preparations there was a concentration dependent decrease in contractile force; the maximal effect amounted to 55.6±6.4% of control while EC50 was reached at 1.0±0.3 nM (n=6). These concentrations are at and even below the therapeutic plasma levels. CsA decreased the aequorin light signal in human failing trabeculae to 71.5±5.9% (n=5), indicating decreased calcium transients. Estimation of the SR calcium load via measurement of rapid cooling contractures revealed a decrease to 84.4±6.5% in failing human preparations (n=6). Measurements of both decreased SR calcium load and force development in presence of CsA were also observed in four non-failing human muscle preparations. In rabbit muscle preparations (n=8), developed force decreased to 50.2±7.7% (n=8, EC50: 1.9±0.4 nM) and rapid cooling contractures to 74.0±7.4% of control at 100 nmol/l CsA. No direct effects were observed on myofilament calcium sensitivity nor on maximal force development of permeabilized preparations from the rabbit (n=7). Oxygen consumption measurements showed that CsA decreased the economy of contraction to 76.4±7.9% in rabbit preparations (n=8). Conclusions: CsA causes a direct cardio-depressive effect at clinically relevant concentrations, most likely due to altered handling of Ca2+ by the SR.
KEYWORDS Calcium (cellular); Contractile function; e–c Coupling; Heart failure; Immunology; Oxygen consumption; SR (function)
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  P. Tavi, S. Pikkarainen, J. Ronkainen, P. Niemela, M. Ilves, M. Weckstrom, O. Vuolteenaho, J. Bruton, H. Westerblad, and H. Ruskoaho Pacing-induced calcineurin activation controls cardiac Ca2+ signalling and gene expression J. Physiol., January 15, 2004; 554(2): 309 - 320. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. J. Wilkins, L. J. De Windt, O. F. Bueno, J. C. Braz, B. J. Glascock, T. F. Kimball, and J. D. Molkentin Targeted Disruption of NFATc3, but Not NFATc4, Reveals an Intrinsic Defect in Calcineurin-Mediated Cardiac Hypertrophic Growth Mol. Cell. Biol., November 1, 2002; 22(21): 7603 - 7613. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. J Wilkins and J. D Molkentin Calcineurin and cardiac hypertrophy: Where have we been? Where are we going? J. Physiol., May 15, 2002; 541(1): 1 - 8. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H A de Groot-Kruseman, C C Baan, E M Hagman, W M Mol, H G Niesters, A P Maat, P E Zondervan, W Weimar, and A H Balk Intragraft interleukin 2 mRNA expression during acute cellular rejection and left ventricular total wall thickness after heart transplantation Heart, April 1, 2002; 87(4): 363 - 367. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 O. F Bueno, E. van Rooij, J. D Molkentin, P. A Doevendans, and L. J De Windt Calcineurin and hypertrophic heart disease: novel insights and remaining questions Cardiovasc Res, March 1, 2002; 53(4): 806 - 821. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H.-P. Hermann, O. Zeitz, S. E Lehnart, B. Keweloh, N. Datz, G. Hasenfuss, and P. M.L Janssen Potentiation of beta-adrenergic inotropic response by pyruvate in failing human myocardium Cardiovasc Res, January 1, 2002; 53(1): 116 - 123. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Most, J. Bernotat, P. Ehlermann, S. T. Pleger, M. Reppel, M. Borries, F. Niroomand, B. Pieske, P. M. L. Janssen, T. Eschenhagen, et al. S100A1: A regulator of myocardial contractility PNAS, November 20, 2001; 98(24): 13889 - 13894. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Mardini, A. S. Mihailidou, A. Wong, and H. H. Rasmussen Cyclosporine and FK506 Differentially Regulate the Sarcolemmal Na+-K+ Pump J. Pharmacol. Exp. Ther., April 12, 2001; 297(2): 804 - 810. [Abstract] [Full Text]
|
|
|
|
|
|
V. J Owen A depressing future for cyclosporine? Cardiovasc Res, July 1, 2000; 47(1): 4 - 5. [Full Text] [PDF]
|
|
|
|
 |
|
 Z. Wang, B. Nolan, W. Kutschke, and J. A. Hill Na+-Ca2+ Exchanger Remodeling in Pressure Overload Cardiac Hypertrophy J. Biol. Chem., May 18, 2001; 276(21): 17706 - 17711. [Abstract] [Full Text] [PDF]
|
|